We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $143M
1-Year Est. Return 102.52%
This Fund
S&P 500
This Quarter Est. Return
+21.15%
1 Year Est. Return
+102.52%
3 Year Est. Return
+167.58%
5 Year Est. Return
+215.85%
10 Year Est. Return
+1,289.38%
AUM
$143M
AUM Growth
+$22.6M
Cap. Flow
+$11.4M
Cap. Flow %
7.98%
Top 10 Hldgs %
39.65%
Holding
91
New
14
Increased
17
Reduced
18
Closed
9

Top Buys

Rank Stock Value
1
IRTC icon
iRhythm Holdings
IRTC
+$3.03M
2
ORKA
Oruka Therapeutics
ORKA
+$2.8M
3
SMMT icon
Summit Therapeutics
SMMT
+$2.67M
4
CBIO
Crescent Biopharma
CBIO
+$2.37M
5
DFTX
Definium Therapeutics
DFTX
+$1.94M

Top Sells

Rank Stock Value
1
EVMN
Evommune Inc
EVMN
+$13.5M
2
GILD icon
Gilead Sciences
GILD
+$905K
3
RAPP
Rapport Therapeutics
RAPP
+$835K
4
BOLD
Boundless Bio
BOLD
+$746K
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$698K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBIO
26
Crescent Biopharma
CBIO
$779M
$2.18M 1.52%
+121,300
New +$2.37M
ROIV icon
27
Roivant Sciences
ROIV
$25B
$2.16M 1.51%
61,100
+28,600
+88% +$845K
IQV icon
28
IQVIA
IQV
$44B
$2.1M 1.46%
10,848
+2,541
+31% +$443K
PLSE icon
29
Pulse Biosciences
PLSE
$3.85B
$1.88M 1.31%
+67,895
New +$1.6M
DHR icon
30
Danaher
DHR
$145B
$1.83M 1.28%
9,597
– –
TMO icon
31
Thermo Fisher Scientific
TMO
$226B
$1.76M 1.23%
3,508
– –
ABT icon
32
Abbott
ABT
$189B
$1.64M 1.14%
18,080
-7,498
-29% -$684K
ATEC icon
33
Alphatec Holdings
ATEC
$1.43B
$1.61M 1.12%
+185,900
New +$1.69M
BSX icon
34
Boston Scientific
BSX
$68.9B
$1.55M 1.08%
36,330
+1,550
+4% +$84.2K
TMDX icon
35
Transmedics
TMDX
$3.03B
$1.46M 1.02%
+21,950
New +$1.86M
CYTK icon
36
Cytokinetics
CYTK
$10.1B
$1.39M 0.97%
16,330
+9,030
+124% +$648K
REGN icon
37
Regeneron Pharmaceuticals
REGN
$85.7B
$1.35M 0.94%
2,169
-750
-26% -$511K
CVS icon
38
CVS Health
CVS
$124B
$1.34M 0.94%
+13,000
New +$1.16M
EW icon
39
Edwards Lifesciences
EW
$51.7B
$1.34M 0.94%
14,826
-2,512
-14% -$210K
TRVI icon
40
Trevi Therapeutics
TRVI
$2.44B
$1.22M 0.85%
65,596
-8,850
-12% -$129K
BMY icon
41
Bristol-Myers Squibb
BMY
$136B
$1.22M 0.85%
21,150
– –
VERA icon
42
Vera Therapeutics
VERA
$2.56B
$1.1M 0.77%
25,573
– –
COGT icon
43
Cogent Biosciences
COGT
$6.03B
$1.03M 0.72%
26,740
+4,600
+21% +$161K
MDT icon
44
Medtronic
MDT
$121B
$876K 0.61%
11,100
– –
TARS icon
45
Tarsus Pharmaceuticals
TARS
$3.71B
$836K 0.58%
13,285
+2,013
+18% +$129K
KURA icon
46
Kura Oncology
KURA
$1.17B
$784K 0.55%
71,480
– –
CNC icon
47
Centene
CNC
$33.5B
$770K 0.54%
+12,000
New +$642K
UTHR icon
48
United Therapeutics
UTHR
$21B
$742K 0.52%
1,370
-340
-20% -$191K
HNGE
49
Hinge Health
HNGE
$7.42B
$726K 0.51%
8,744
-3,500
-29% -$190K
NKTR icon
50
Nektar Therapeutics
NKTR
$2.53B
$706K 0.49%
10,111
-740
-7% -$54.1K
1
2
3 4

Similar funds

ICMP
Integrated Capital Management (Pennsylvania) Jessup, Pennsylvania $143M AUM 18.2% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
SL
Sonnipe Ltd Douglas, Isle Of Man $143M AUM 76.98% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Sectoral Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Sectoral Asset Management held 91 positions worth $143M, up 19% from $121M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Sectoral Asset Management deployed $11.4M of net new capital in Q2 2026, opening 14 new positions and adding to 17 existing holdings. Its largest new stake was iRhythm Holdings: 26,070 shares worth $3.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $905K trimmed.

  • Sectoral Asset Management's largest Q2 2026 buy was iRhythm Holdings: 26,070 shares worth $3.1M.
  • Sectoral Asset Management added most to Summit Therapeutics in Q2 2026, an estimated $2.67M increase.
  • Sectoral Asset Management's biggest Q2 2026 reduction was Gilead Sciences, cutting an estimated $905K.
  • Sectoral Asset Management fully exited Evommune Inc in Q2 2026, selling an estimated $13.5M.
  • Sectoral Asset Management's ten largest holdings make up 40% of its $143M portfolio in Q2 2026.
  • Sectoral Asset Management opened 14 new positions and closed 9 in Q2 2026.
  • Sectoral Asset Management's portfolio value rose 19% quarter-over-quarter to $143M.

Based on Sectoral Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.